Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001209191-20-025893)

Filing Details

Accession Number:: 0001209191-20-025893
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-04-28 13:43:42
Reporting Period:: 2020-04-26

Accepted Time:: 2020-04-28 13:43:42
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1668243	Urogen Pharma Ltd.	URGN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1764139	Stephen Mullennix	C/O Urogen Pharma Ltd. 400 Alexander Park Princeton NJ 08540	Chief Operating Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2020-04-26	417	$0.00	10,229	No	4	M	Direct
Ordinary Shares	Disposition	2020-04-27	145	$24.35	10,084	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Restricted Stock Units (RSUs)	Disposition	2020-04-26	417	$0.00	417	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2,917			No	4	M	Direct

Footnotes

Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
The reporting person was granted 5,000 Restricted Stock Units ("RSUs") on January 26, 2019. 33.33% of the RSUs vested on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter.